Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics将参加H.C. Wainwright第二届年度BioConnect投资者会议
Download as PDF May 13, 2024
以 PDF 格式下载 2024 年 5 月 13 日
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.
马萨诸塞州沃尔瑟姆，2024年5月13日（GLOBE NEWSWIRE）——临床阶段免疫疗法和靶向肿瘤公司Checkpoint Therapeutics, Inc.（“Checkpt”）（纳斯达克股票代码：CKPT）今天宣布，总裁兼首席执行官詹姆斯·奥利维罗将参加2024年5月20日星期一在纳斯达克举行的H.C. Wainwright第二届年度生物连接投资者会议的炉边谈话，美国东部时间下午 12:30Checkpoint还将在会议期间参加面对面的一对一会议。
A webcast of the fireside chat will be available on the News & Events page, located within the Investors section of Checkpoint's website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.
炉边谈话的网络直播将在Checkpoint网站投资者部分的新闻与活动页面上播出， https://ir.checkpointtx.com/event-calendar/default.aspx，在会后约30天内举行。
About Checkpoint Therapeutics
关于检查点疗法
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.
Checkpoint Therapeutics, Inc. 是一家临床阶段的免疫疗法和靶向肿瘤学公司，专注于实体瘤癌患者新疗法的收购、开发和商业化。Checkpoint正在评估其主要候选抗体产品cosibelimab，一种潜在的最佳抗PD-L1抗体，该抗体由达纳-法伯癌症研究所授权，是特定复发性或转移性癌症（包括转移性和局部晚期cSCC）患者的潜在新疗法。Checkpoint还在评估其领先的小分子靶向抗癌药物奥法替尼（前身为 CK-101），这是一种第三代表皮生长因子受体（“EGFR”）抑制剂，作为表皮生长因子突变阳性非小细胞肺癌患者的潜在新疗法。Checkpoint总部位于马萨诸塞州沃尔瑟姆，由丰泽生物技术公司（纳斯达克股票代码：FBIO）创立。欲了解更多信息，请访问 www.checkpointtx.com。
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
公司联系人：
Jaclyn Jaffe
Checkpoint Therapeu
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
投资者关系联系人：
阿什莉·罗宾逊
LifeSCI Advisors, LLC董事总经理
(617) 430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
媒体关系联系人：
凯蒂肯尼迪
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
Source: Checkpoint Therapeutics, Inc
资料来源：检查点疗法公司
Released May 13, 2024
2024 年 5 月 13 日发布